URINARY ENDOTHELIN - A POSSIBLE BIOLOGICAL MARKER OF RENAL DAMAGE

被引：42

作者：

ABASSI, ZA

KLEIN, H

GOLOMB, E

KEISER, HR

机构：

[1] Hypertension-Endocrine Branch, National Heart, Lung and Blood Institute, Bethesda, MD, Bldg. 10, National Institutes of Health

[2] From the Hypertension-Endocrine Branch, National Heart, Lung and Blood Institute, Bethesda, MD, National Institutes of Health

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1993年 / 6卷 / 12期

关键词：

ENDOTHELIN; RENAL FAILURE; DIABETES MELLITUS; URINARY ENDOTHELIN;

D O I：

10.1093/ajh/6.12.1046

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Endothelin (ET) is a powerful vasoconstrictor peptide synthesized and secreted by the vascular endothelium. Significant amounts of ET are also produced by nonendothelial cells, mainly tubular-epithelial and mesangial cells. Large amounts of ET are found in the urine compared with the small amounts present in blood. Because most of the ET filtered from plasma is subject to degradation by neutral endopeptidase (EC 3.4.24.11) in the proximal tubule, urinary ET is probably of renal origin. The range of urinary ET excretion in healthy persons is 20 to 90 ng/day. The excretion of endothelin is modulated by several mechanical and chemical stimuli such as angiotensin IT, phenylephrine, radiocontrast media, cyclosporine, and cis-platin. In addition, enhanced urinary ET excretion has been found in several forms of renal failure, both acute and chronic, and in diabetes mellitus. Thus, urinary ET has the potential of serving as a marker for renal disease.

引用

页码：1046 / 1054

页数：9

共 96 条

[1]

Yanagisawa M., Kurihara H., Kimura S., Et al., A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature, 332, pp. 411-415, (1988)

[2]

Zeidel M.L., Brady H., Kone B., Endothelin, a pep¬ tide inhibitor of Na +-K +-ATPase in intact renal tu¬ bular epithelial cells, Am J Physiol, 257, pp. C1101-C1107, (1989)

[3]

Whittle B.J., Payne A.N., Esplungues J.V., Cardiopulmo¬ nary and gastric ulcerogenic actions of endothelin-1 (ET-1) in the guinea pig and rat, J Cardiovasc Phar¬ Macol, 13, pp. S103-S107, (1989)

[4]

Filep G.J., Endothelin peptides: Biological and patho¬ physiological significance in the lung, Life Sci, 52, pp. 119-133, (1993)

[5]

Filep J.G., Sirois M.G., Rousseau A., Et al., Effects of en- dothelin-1 on vascular permeability in the conscious rat: Interactions with platelet-activating factor, Br J Pharmacol, 104, pp. 797-804, (1991)

[6]

Zimmerman R.S., Martinez A.J., Maymind M., Barbee R.W., Effect of endothelin on plasma volume and albu¬ min escape, Circ Res, 70, pp. 1027-1034, (1992)

[7]

Dubin D., Pratt R.E., Cooke J.P., Dzau V.J., Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen, J Vase Med Biol, 1, pp. 150-154, (1989)

[8]

Luscher T.F., Zhihong Y., Diederich D., Buhler F.R., En¬ dothelium-derived vasoactive and vascular sub¬ stances: Potential role in hypertension, atherosclerosis and vascular occlusion, J Cardiovasc Pharmacol, 14, pp. S63-S69, (1989)

[9]

Takahashi K., Ghatei M.A., Jones P.M., Et al., Endothelin in human brain and pituitary gland: Presence of im- munoreactive endothelin, messenger ribonucleic acid, and endothelin receptors, J Clin Endocrinol Metab, 72, pp. 693-699, (1991)

[10]

← 1 2 3 4 5 6 7 8 9 10 →